HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic and similar GLP-1 receptor agonists are not approved by the FDA for fertility or pregnancy support. However, emerging data suggest that metabolic improvements from GLP-1 therapy may benefit ovulation in women with polycystic ovary syndrome (PCOS) or insulin resistance. Understanding the science—and your individual biomarker profile—is critical before considering any peptide therapy alongside conception planning.

Women exploring GLP-1 medications while trying to conceive face complex decisions. This requires evaluating your metabolic health, understanding medication safety during pregnancy and nursing, and working closely with reproductive endocrinologists. PlexusDx supports this precision-wellness approach by helping you understand how your metabolic and genetic profile may inform these conversations.

GLP-1 Receptor Agonists and Female Fertility: What Research Actually Shows

The evidence linking GLP-1 medications to fertility outcomes is indirect. Most data come from observational studies in women with PCOS or obesity-related infertility. Improvements in ovulation appear tied to weight loss and insulin sensitivity improvements, not the GLP-1 mechanism itself. No randomized controlled trials have assessed Ozempic or semaglutide specifically for fertility enhancement.

A 2022 systematic review found that modest weight loss (5–10%) from any intervention can restore ovulation in anovulatory women with PCOS. GLP-1 medications may facilitate this weight loss more effectively than diet alone in some patients. However, rapid weight loss during conception attempts carries its own risks and requires close provider oversight.

Metabolic Biomarkers That Matter for Fertility and GLP-1 Consideration

Before starting any GLP-1 medication while planning pregnancy, assessing metabolic status is essential. Key biomarkers include insulin levels, fasting glucose, HOMA-IR (insulin resistance index), testosterone, and ovulatory hormones. These markers help your provider determine whether GLP-1 therapy addresses root causes of infertility or introduces unnecessary risk.

Biomarker Fertility Relevance Why It Matters for GLP-1 Decisions
Fasting Insulin / HOMA-IR High insulin resistance impairs ovulation and increases miscarriage risk GLP-1 improves insulin sensitivity; baseline assessment reveals whether this benefit applies to your case
Fasting Glucose Dysglycemia linked to anovulation and poor egg quality GLP-1 improves glucose control; establishing baseline helps measure benefit and track safety during conception
Free Testosterone Elevated in PCOS; suppresses ovulation and fertility GLP-1-induced weight loss may lower androgens; baseline helps confirm mechanism of benefit
AMH / FSH Markers of ovarian reserve and menstrual cycle regulation Essential baseline before any hormone-affecting therapy; helps rule out premature ovarian insufficiency

Safety Considerations: Pregnancy, Nursing, and Medication Continuity

GLP-1 medications are Pregnancy Category C (some sources suggest B for semaglutide). This means animal studies show some risk, but human data are limited. No major birth defects have been linked to GLP-1 exposure in published case reports, but most fertility specialists recommend discontinuing GLP-1 therapy once pregnancy is confirmed, as no safety data exist for fetal exposure.

Rapid weight loss during the first trimester may impair fetal development. If you conceive while on a GLP-1 medication, prompt consultation with your obstetrician and reproductive endocrinologist is critical. Breastfeeding while on GLP-1 agents is not well-studied. Many providers recommend waiting to restart GLP-1 until after nursing ends. These decisions are individual and require qualified medical oversight.

Who Should Consider GLP-1 Therapy in Conception Planning: Provider Decision Framework

GLP-1 therapy may be worth exploring—under close medical supervision—if you have PCOS or obesity-related infertility, elevated insulin resistance, documented anovulation, and failed conventional fertility interventions. Your reproductive endocrinologist should confirm that weight loss and metabolic improvement, not the GLP-1 drug itself, are the intended therapeutic mechanisms. Compounded or branded formulations carry identical mechanism and safety profiles; provider preference determines choice.

GLP-1 is not appropriate if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pregnancy confirmed or strongly suspected, planned fertility treatment within 3 months, or a history of pancreatitis. A thorough fertility workup—including thyroid function, ovarian reserve, partner evaluation, and structural assessment—should precede any GLP-1 consideration. This is a personalized clinical judgment, not a standard-of-care fertility intervention.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your individual genetic profile in peptide signaling pathways (GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609) relates to insulin sensitivity and metabolic response. These variants reveal predispositions in how your body responds to metabolic stress and weight change—information that can support a more informed conversation with your fertility provider about whether GLP-1 therapy addresses your specific biological drivers of infertility.

The genetic test does not predict whether you will or will not conceive on a GLP-1 medication, nor does it diagnose PCOS or infertility. Instead, it reveals inherited patterns in glucose sensing, appetite regulation, and fat metabolism. When interpreted with your metabolic biomarkers (insulin, glucose, testosterone), your genetic profile can help your provider distinguish whether GLP-1-induced metabolic improvement might benefit your specific case.

If you are exploring GLP-1 therapy as part of conception planning, discussing both your biomarker panel and genetic predispositions with your reproductive endocrinologist can support a data-informed decision. PlexusDx compounded semaglutide and tirzepatide options are available at various dose levels, allowing your provider to tailor therapy to your individual metabolic needs—but only after confirming that GLP-1 therapy aligns with your fertility goals and safety profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.